Company intelligence / Profile preview

Probionova

Lugano, Ticino, Switzerlandpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Probionova develops and produces evidence-based probiotics with pharmaceutical-grade quality, targeting the improvement of human gut and digestive health. The company collaborates with scientific experts to advance research on the human microbiome, offering innovative probiotic formulations for therapeutic and supplement markets. Clinical results are referenced as "evidence-based," but no specific trial outcomes are published in public sources as of June 2025.

Therapeutic areas: Gastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapyDietary supplement (probiotic-based)
Industry: Biotech

Drug pipeline

1 asset

LCR Regenerans

Beyond the preview

Go deeper on Probionova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probionova.

Explore the full profile